Heart failure biomarkers

Journal of Cardiovascular Translational Research

Volumn 6, Issue 4, 2013, Pages 471-484

  Choudhary, Rajiv ^a   Iqbal, Navaid ^b   Khusro, Fatima ^b   Higginbotham, Erin ^b   Green, Erik ^b   Maisel, Alan ^b  

^a Department of Medicine   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

Acute heart failure; Biomarkers; Emergency department; Heart failure; Heart failure therapy

Indexed keywords

ADRENOMEDULLIN; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; COPEPTIN; GALECTIN 3; GROWTH DIFFERENTIATION FACTOR 15; INTERLEUKIN 1 RECEPTOR; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PROCALCITONIN; ST2 PROTEIN; TROPONIN; TROPONIN T; UNCLASSIFIED DRUG;

ARTICLE; CELL STRESS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CELL; HUMAN; KIDNEY DYSFUNCTION; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY;

ANIMALS; BIOLOGICAL MARKERS; HEART FAILURE; HUMANS; MYOCYTES, CARDIAC; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 84880511725     PISSN: 19375387     EISSN: 19375395     Source Type: Journal    
DOI: 10.1007/s12265-013-9465-0     Document Type: Article

References (105)

1. O'Connor, C. M.; Abraham, W. T.; Albert, N. M.; et al. (2008). Predictors of mortality after discharge in patients hospitalized with heart failure: An analysis for the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). American Heart Journal, 156, 662-673.
2. Weintraub, N. L.; Collins, S. P.; Pang, P.; et al. (2010). Acute heart failure syndromes: Emergency department presentation, treatment, and disposition: Current approaches and future aims. Circulation, 122, 1975-1996.
3. Fonarow, G. C.; Heywood, J. T.; Heidenreich, P. A.; et al. (2007). Temporal trends in clinical characteristics, treatments and outcomes for heart failure hospitalizations, 2002 to 2004: Findings from Acute Decompensated Heart Failure National Registry (ADHERE). American Heart Journal, 153, 1021-1028.
4. Follath, F.; Yilmaz, M. B.; Delgado, J. F.; et al. (2011). Clinical presentation, management and outcomes in the Acute Heart Failure Global Survey of Standard Treatment (ALARM-HF). Intensive Care Medicine, 37, 619-626.
5. Morrow, D. A.; & De Lemos, J. A. (2007). Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation, 115, 949-952.
6. Mukoyama, M.; Nakao, K.; Hosoda, K.; et al. (1991). Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. The Journal of Clinical Investigation, 87, 1402-1412.
7. Sudoh, T.; Kangawa, K.; Minamino, N.; & Matsuo, H. (1998). A new natriuretic peptide in the porcine brain. Nature, 332, 78-81.
8. Yasue, H.; Yoshimura, M.; Sumida, H.; Kikuta, K.; Kugiyama, K.; Jougasaki, M.; et al. (1994). Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation, 90, 195-203.
9. Potter, L. R.; Abbey-Hosch, S.; & Dickey, D. M. (2006). Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocrine Reviews, 25, 47-72.
10. Richards, A. M.; & Troughton, R. (2012). Use of natriuretic peptides to guide and monitor heart failure therapy. Clinical Chemistry, 58, 67-71.
11. Kim, H. N.; & Januzzi, L. J.; Jr. (2009). Natriuretic peptides testing for heart failure therapy guidance in the inpatient and outpatient setting. American Journal of Therapy, 16, 171-177.
12. Kazanegra, R.; Cheng, V.; Garcia, A.; Krishnaswamy, P.; Gardetto, N.; Clopton, P.; et al. (2001). A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: A pilot study. Journal of Cardiac Failure, 7, 21-29.
13. Maisel, A. S.; Krishnaswamy, P.; Nowak, R. M.; McCord, J.; Hollander, J. E.; Duc, P.; et al. (2002). Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. The New England Journal of Medicine, 347, 161-167.
14. McCullough, P. A.; Nowak, R. M.; McCord, J.; Hollander, J. E.; Herrmann, H. C.; Steg, P. G.; et al. (2002). B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: Analysis from Breathing Not Properly (BNP) Multinational Study. Circulation, 106, 416-422.
15. Maisel, A.; Hollander, J. E.; Guss, D.; McCullough, P.; Nowak, R.; Green, G.; et al. (2004). Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. Journal of the American College of Cardiology, 44, 1328-1333.
16. Brenden, C. K.; Hollander, J. E.; Guss, D.; McCullough, P. A.; Nowak, R.; Green, G.; et al. (2006). Gray zone BNP levels in heart failure patients in the emergency department: Results from the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT) multicenter study. American Heart Journal, 15(5), 1006-1011.
17. Fonarow, G. C.; Peacock, W. F.; Phillips, C. O.; Givertz, M. M.; Lopatin, M.; et al. (2007). Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. Journal of the American College of Cardiology, 49, 1943-1950.
18. Berger, R.; Huelsman, M.; Strecker, K.; Bojic, A.; Moser, P.; Stanek, B.; et al. (2002). B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation, 105, 2392-2397.
19. Verdiani, V.; Nozzoli, C.; Bacci, F.; Cecchin, A.; Rutili, M. S.; Paladini, S.; et al. (2005). Pre-discharge B-type natriuretic peptide predicts early recurrence of decompensated heart failure in patients admitted to a general medical unit. European Journal of Heart Failure, 7, 566-571.
20. Logeart, D.; Thabut, G.; Jourdain, P.; Chavelas, C.; Beyne, P.; Beauvais, F.; et al. (2004). Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. Journal of the American College of Cardiology, 43, 635-641.
21. Valle, R.; Aspromonte, N.; Giovinazzo, P.; Carbonieri, E.; Chiatto, M.; di Tano, G.; et al. (2008). B-type natriuretic peptide-guided treatment for predicting outcome in patients hospitalized in sub-intensive care unit with acute heart failure. Journal of Cardiac Failure, 14, 219-224.
22. Hunt, P. J.; Richards, A. M.; Nicholls, M. G.; Tangle, T. G.; Doughty, R. N.; & Espiner, E. A. (1997). Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): A new marker of cardiac impairment. Clinical Endocrinology, 3, 287-296.
23. Nielsen, L. S.; Svanegaard, J.; Klitgaard, N. A.; & Egeblad, H. (2004). N-terminal pro-brain natriuretic peptide for discriminating between cardiac and non-cardiac dyspnoea. European Journal of Heart Failure, 6, 63-70.
24. Richards, A. M.; Doughty, R.; Nicholls, M. G.; MacMahon, S.; Sharpe, N.; & Murphy, J. (2001). Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: Prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. Journal of the American College of Cardiology, 37, 1781-1787.
25. Groenning, B. A.; Raymond, I.; Hildereandt, P. R.; Nilsson, J. C.; Baumann, M.; & Pedersen, F. (2004). Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population. Heart, 90, 297-303.
26. Moe, G. W.; Howlett, J.; Januzzi, J. L.; Zowall, H.; et al. (2007). N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: Primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. Circulation, 115, 3103-3110.
27. Hartmann, F.; Packer, M.; Coats, A. J.; Fowler, M. B.; Krum, H.; Mohacsi, P.; et al. (2004). Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: A substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation, 110, 1780-1786.
28. Bettencourt, P.; Azevedo, A.; Pimenta, J.; Frioes, F.; Ferreira, S.; & Ferreira, A. (2004). N-terminal pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation, 110, 2168-2174.
29. Gardner, R. S.; Chong, K. S.; Morton, J. J.; & McDonagh, T. A. (2007). A change in N-terminal pro-brain natriuretic peptide is predictive of outcome in patients with advanced heart failure. European Journal of Heart Failure, 9, 266-271.
30. Gardner, R. S.; Ozalp, F.; Murday, A. J.; Robb, S. D.; & McDonagh, T. A. (2003). N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. European Heart Journal, 24, 1735-1743.
31. Mir, T. S.; Marohn, S.; Laer, S.; Eiselt, M.; Grollmus, O.; & Weil, J. (2002). Plasma concentrations of N-terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure. Pediatrics, 110, e76.
32. Lainchbury, J. G.; Troughton, R. W.; Strangman, K. M.; Frampton, C. M.; Pilbrow, A.; Yandle, T. G.; et al. (2009). N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: Results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. Journal of the American College of Cardiology, 55, 53-60.
33. Waldo, S. W.; Beede, J.; Isakson, S.; Villard-Saussine, S.; Fareh, J.; Clopton, P.; et al. (2008). Pro-B-type natriuretic peptide levels in acute decompensated heart failure. Journal of the American College of Cardiology, 51, 1874-1882.
34. Lainchbury, J. G.; Campbell, E.; Frampton, C. M.; Tandle, T. G.; Nicholls, G.; & Richards, A. M. (2003). Brain natriuretic peptide and N-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. Journal of the American College of Cardiology, 42, 728-735.
35. Masson, S.; Latini, R.; Anand, I. S.; Vago, T.; Angelici, L.; Barlera, S.; et al. (2006). Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: The Valsartan Heart Failure (Val-HeFT) data. Clinical Chemistry, 52, 1528-1538.
36. Pemberton, C. J.; Johnson, M. L.; Tangle, T. G.; & Espiner, E. A. (2000). Deconvolution analysis of cardiac natriuretic peptides during acute volume overload. Hypertension, 36, 355-359.
37. Mair, J.; Falkensammer, G.; Poelzl, G.; Hammerer-Lercher, A.; Griesmacher, A.; & Pachinger, O. (2007). B-type natriuretic peptide (BNP) is more sensitive to rapid hemodynamic changes in acute heart failure than N-terminal proBNP. Clinica Chimica Acta, 379(1-2), 163-166.
38. Kragelund, C.; & Omland, T. (2005). B-type natriuretic peptide (BNP) or N-terminal-proBNP for the diagnosis of heart failure: Which peptide is the better choice? Scandinavian Journal of Clinical and Laboratory Investigation, 65, 629-632.
39. Mueller, T.; Gegenhuber, A.; Poelz, W.; & Haltmayer, M. (2005). Diagnostic accuracy of B type natriuretic peptide and amino terminal proBNP in the emergency diagnosis of heart failure. Heart, 91, 606-612.
40. Maisel, A. S.; et al. (2010). Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: Results from the BACH (Biomarkers in Acute Heart Failure) trial. Journal of the American College of Cardiology, 55, 2062-2076.
41. Morgenthaler, N. G.; Struck, J.; Thomas, B.; & Bergmann, A. (2004). Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clinical Chemistry, 50, 234-236.
42. Potocki, M.; Breidthardt, T.; Reichlin, T.; et al. (2010). Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in the diagnosis of heart failure. Journal of Internal Medicine, 267(1), 119-129.
43. Moertl, D.; et al. (2009). Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure. Journal of the American College of Cardiology, 53, 1783-1790.
44. Eto, T. (2001). A review of the biological properties and clinical implications of adrenomedullin and proadrenomedullin N-terminal 20 peptide (PAMP), hypotensive and vasodilating peptides. Peptides, 22, 1693-1711.
45. Beltowski, J.; & Jamroz, A. (2004). Adrenomedullin - What do we know 10 years since its discovery? Polish Journal of Pharmacology, 56, 5-27.
46. Jougasaki, M.; & Burnett, J. C.; Jr. (2000). Adrenomedullin: Potential in physiology and pathophysiology. Life Science, 66(10), 855-872.
47. Maisel, A.; Mueller, C.; Nowak, R.; et al. (2010). Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: Results from the BACH (Biomarkers in Acute Heart Failure) trial. Journal of the American College of Cardiology, 55(19), 2062-2076.
48. Morgenthaler, N. G.; Struck, J.; Alonso, C.; et al. (2005). Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clinical Chemistry, 51, 1823-1829.
49. Klip, I. T.; Voors, A. A.; Anker, S. D.; Hillege, H. L.; Struck, J.; Squire, I.; et al. (2011). Prognostic value of mid-regional pro-adrenomedullin in patients with HF after an acute myocardial infarction. Heart, 97, 892-898.
50. Peacock, W. F.; Nowak, R.; Christenson, R.; DiSomma, S.; Neath, S. X.; Hartmann, O.; et al. (2011). Short-term mortality risk in emergency department acute heart failure. Academic Emergency Medicine, 18(9), 947-958.
51. Haehling, S.; Filippatos, G.; Papassotiriou, J.; et al. (2010). Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure. European Journal of Heart Failure, 12, 484-491.
52. Dhillon, O.; Khan, S.; Narayan, H.; et al. (2010). Prognostic value of mid-regional pro-adrenomedullin levels taken on admission and discharge in non-ST-elevation myocardial infarction: The LAMP (Leicester Acute Myocardial Infarction Peptide) II Study. Journal of the American College of Cardiology, 56, 125-133.
53. Shah, R. V.; Truong, Q. A.; Gaggin, H. K.; Pfannkuche, J.; Hartmann, O.; & Januzzi, J. L.; Jr. (2012). Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea. European Heart Journal, 33(17), 2197-2205.
54. Haider, K. H.; & Stimson, W. H. (1993). Cardiac troponin-I: A biochemical marker for cardiac cell necrosis. Disease Markers, 11(5-6), 205-215.
55. Missov, E.; Calzolari, C.; & Pau, B. (1997). Circulating cardiac troponin I in severe congestive heart failure. Circulation, 96, 2953-2958.
56. Vecchia, L. L.; Mezzena, G.; Zanolla, L.; Paccanaro, M.; Varotto, L.; Conanno, C.; et al. (2000). Cardiac troponin I as diagnostic and prognostic marker in severe heart failure. The Journal of Heart and Lung Transplantation, 19, 644-652.
57. Dinh, W.; et al. (2011). High sensitive troponin T and heart fatty acid binding protein: Novel biomarker in heart failure with normal ejection fraction? A cross-sectional study. BMC Cardiovascular Disorders, 11, 41.
58. Reichlin, T.; et al. (2009). Early diagnosis of myocardial infarction with sensitive troponin assays. The New England Journal of Medicine, 361, 858-867.
59. Stanton, E. B.; Hansen, M. S.; Sole, M. J.; Gawad, Y.; Packer, M.; Pitt, B.; et al. (2005). Cardiac troponin I, a possible predictor of survival in patients with stable congestive heart failure. Canadian Journal of Cardiology, 21, 39-43.
60. Peacock, W. F.; De Marco, T.; Fonarow, G. C.; Diercks, D.; Wynne, J.; Apple, F. S.; et al. (2008). Cardiac troponin and outcome in acute heart failure. The New England Journal of Medicine, 358, 2117-2126.
61. Xue, Y.; Clopton, P.; Peacock, W. F.; & Maisel, A. S. (2011). Serial changes in high-sensitive troponin I predict outcome in patients with decompensated heart failure. European Journal of Heart Failure, 13(1), 37-42.
62. Felker, G. M.; Hasselblad, V.; Wilson Tang, W. H.; Hernandez, A. F.; Armstrong, P. W.; Fonarow, G. C.; et al. (2012). Troponin I in acute decompensated heart failure: Insights from the ASCEND-HF study. European Journal of Heart Failure, 14(11), 1257-1264.
63. Bootcov, M. R.; Bauskin, A. R.; Valenzuela, S. M.; Moore, A. G.; Bansal, M.; He, X. Y.; et al. (1997). MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proceedings of the National Academy of Sciences of the United States of America, 94, 11514-11519.
64. Fairlie, W. D.; Moor, A. G.; Bauskin, A. R.; Russel, P. K.; Zhang, H. P.; & Breit, S. N. (1999). MIC-1 is a novel TGF-beta superfamily cytokine associated with macrophage activation. Journal of Leukocyte Biology, 65, 2-5.
65. Xu, J.; Kimball, T. R.; Lorenz, J. N.; Brown, D. A.; Bauskin, A. R.; Klevitsky, R.; et al. (2006). GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circulation Research, 98, 342-350.
66. Kempf, T.; Eden, M.; Strelau, J.; Naguib, M.; Willenbockel, C.; Tongers, J.; et al. (2006). The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circulation Research, 98, 351-360.
67. Lind, L.; Wallentin, L.; Kempf, T.; Tapken, H.; Quint, A.; Lindahl, B.; et al. (2009). Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: Results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study. European Heart Journal, 30, 2346-2353.
68. Daniels, L. B.; Clopton, P.; Laughlin, G. A.; Maisel, A. S.; & Barrett-Connor, E. (2011). Growth-differentiation factor-15 is a robust, independent predictor of 11-year mortality risk in community-dwelling older adults: The Rancho Bernardo Study. Circulation, 123, 2101-2110.
69. Kempf, T.; von Haeling, S.; Peter, T.; Allhoff, T.; Cicoira, M.; Doehner, W.; et al. (2007). Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. Journal of the American College of Cardiology, 50(11), 1054-1060.
70. Devarajan, P.; & Neutrophil gelatinase-associated lipocalin (NGAL). (2008). A new marker of kidney disease. Scandinavian Journal of Clinical and Laboratory Investigation Supplementum, 241, 89-94.
71. Goetz, D. H.; Willie, S. T.; Armen, R. S.; et al. (2000). Ligand preference inferred from the structure of neutrophil gelatinase associated lipocalin. Biochemistry, 39, 1935-1941.
72. Bolignano, D.; Donato, V.; Coppolino, G.; et al. (2008). Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. American Journal of Kidney Diseases, 52, 595-605.
73. Bellomo, R.; Ronco, C.; Kellum, J.; et al. (2004). Acute renal failure - Definition, outcome measures, animal models, fluid therapy and information technology needs: The second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Critical Care, 8, R204-R212.
74. Mishra, J.; Dent, C.; Tarabishi, R.; et al. (2005). Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. The Lancet, 365, 1231-1238.
75. Maisel, A. S.; Mueller, C.; Fitzgerald, R. L.; et al. (2011). Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: The NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial. European Journal of Heart Failure, 13, 846-851.
76. Torregrosa, I.; Montoliu, C.; Urios, A.; et al. (2012). Early biomarkers of acute kidney failure after heart angiography or heart surgery in patients with acute coronary syndrome or acute heart failure. Nefrología, 32(1), 44-52.
77. Haase, M.; Devarajan, P.; Haase-Fielitz, A.; et al. (2011). The outcome of neutrophil gelatinase-associated lipocalin-positive subclinical acute kidney injury: A multicenter pooled analysis of prospective studies. Journal of the American College of Cardiology, 57, 1752-1761.
78. Nickolas, T. L.; Schmidt-Ott, K. M.; Canetta, P.; Forster, C.; Singer, E.; Sise, M.; et al. (2012). Diagnostic and prognostic stratification in the emergency department using urinary biomarkers of nephron damage: A multicenter prospective cohort study. Journal of the American College of Cardiology, 59(3), 246-255.
79. Aghel, A.; Shreshta, K.; Mullens, W.; Borowski, A.; & Tang, W. H. (2010). Serum neutrophil gelatinase-associated lipocalin (NGAL) in predicting worsening renal function in acute decompensated heart failure. Journal of Cardiac Failure, 16, 49-54.
80. Thomsen, R. W.; Kasatpibal, N.; Riis, A.; et al. (2008). The impact of pre-existing heart failure on pneumonia prognosis: Population-based cohort study. Journal of General Internal Medicine, 23(9), 1407-1413.
81. Corrales-Medina, V. F.; Musher, D. M.; Wells, G. A.; et al. (2012). Cardiac complications in patients with community-acquired pneumonia - Incidence, timing, risk-factors, and association with short-term mortality. Circulation, 125, 773-781.
82. Musher, D. M.; Rueda, A. M.; Kaka, A. S.; & Mapara, S. M. (2007). The association between pneumococcal pneumonia and acute cardiac events. Clinical Infectious Diseases, 45, 158-165.
83. Assicot, M.; Gendrel, D.; Carsin, H.; et al. (1993). High serum procalcitonin concentrations in patients with sepsis and infection. The Lancet, 341, 515-518.
84. Christ-Crain, M.; Stolz, D.; Bingisser, R.; et al. (2006). Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: A randomized trial. American Journal of Respiratory and Critical Care Medicine, 174, 84-93.
85. Nijsten, M.; Olinga, P.; Hauw, T. T.; et al. (2000). Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro. Critical Care Medicine, 28, 458-461.
86. Maisel, A. S.; Neath, S. X.; Landsberg, J.; Mueller, C.; et al. (2012). Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea: Results from the BACH (Biomarkers in Acute Heart Failure) trial. European Journal of Heart Failure, 14, 278-286.
87. Dabla, P. K.; Dabla, V.; & Arora, S. (2011). Co-peptin: Role as a novel biomarker in clinical practice. Clinica Chimica Acta, 412, 22-28.
88. Szinnai, G.; Morgenthaler, N. G.; Berneis, K.; et al. (2007). Changes in plasma copeptin, the c-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects. Journal of Clinical Endocrinology and Metabolism, 92, 3973-3978.
89. Morgenthaler, N. G.; Struck, J.; Alonso, C.; & Bergman, A. (2006). Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clinical Chemistry, 52, 112-119.
90. Stoiser, B.; et al. (2006). Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. European Journal of Clinical Investigation, 36, 771-778.
91. Voors, A. A.; et al. (2009). C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: Results from OPTIMAAL study. European Heart Journal, 30, 1187-1194.
92. Peacock, W. F.; et al. (2011). Short-term mortality risk in emergency department acute heart failure. Academic Emergency Medicine, 18, 947-958.
93. Iwahana, H.; Yanagisawa, K.; Ito-Kosaka, A.; Kuroiwa, K.; Tago, K.; Komatsu, N.; et al. (1999). Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells. European Journal of Biochemistry, 264, 397-406. doi: 10.1046/j.1432-1327.1999.00615.
94. Weinberg, E. O.; Shimpo, M.; De Keulenaer, G. W.; MacGillivray, C.; Tominaga, S.; Solomon, S. D.; et al. (2002). Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation, 106, 2961-2966.
95. Januzzi, J. L.; Jr.; Peacock, W. F.; Maisel, A. S.; et al. (2007). Measurement of the interleukin family member ST2 in patients with acute dyspnea: Results from the PRIDE study. Journal of the American College of Cardiology, 50, 607-613.
96. Ky, B.; French, B.; McCloskey, K.; Rame, J. E.; McIntosh, E.; Shahi, P.; et al. (2011). High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circulation Heart Failure, 4, 180-187.
97. Rehman, S. U.; Mueller, T.; & Januzzi, J. L.; Jr. (2008). Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. Journal of the American College of Cardiology, 52, 1458-1465.
98. Boisot, S.; Beede, J.; Isakson, S.; Chiu, A.; Clopton, P.; Januzzi, J. L.; et al. (2008). Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. Journal of Cardiac Failure, 14, 732-738.
99. Sharma, U. C.; et al. (2004). Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation, 110, 3121-3128.
100. De Boer, R. A.; Voors, A. A.; Mutendam, P.; van Gilst, W. H.; & van Veldhuisen, D. J. (2009). Galectin-3: A novel mediator of heart failure development and progression. European Journal of Heart Failure, 11, 811-817.
101. van Kimmenade, R. R.; Januzzi, J. L.; Jr.; Ellinor, P. T.; Sharma, U. C.; Bakker, J. A.; Low, A. F.; et al. (2006). Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. Journal of the American College of Cardiology, 48, 1217-1224.
102. Lok, D. J.; Lok, S. I.; Bruggink-Andre de la Porte, P. W.; Badings, E.; Lipsic, E.; Wijngaarden, J. V.; et al. (2013). Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clinical Research in Cardiology, 102(2), 103-110.
103. van der Velde, A. R.; Gullestad, L.; Ueland, T.; Aukrust, P.; Guo, Y.; Adourian, A. S.; Muntendam, P.; et al. (2013). Prognostic value of changes in galectin-3 levels over time in patients with heart failure: Data from CORONA and COACH. Circulation: Heart Failure, 6, 219-226.
104. Gopalm, D. M.; Kommineni, M.; Ayalon, N.; et al. (2012). Relationship of plasma galectin-3 to renal function in patients with heart failure: Effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure. Journal of American Heart Association, e00760. doi: 10.1161/JAHA.112.000760.
105. Felker, G. M.; Fiuzat, M.; Shaw, L. K.; et al. (2012). Galectin-3 in ambulatory patients with heart failure: Results from the HF-ACTION study. Circulation Heart Failure, 5, 72-78.